VJHemOnc is committed to improving our service to you

IACH Focus on Leukemia 2020 | Clinical trials investigating tagraxofusp in BPDCN and beyond

VJHemOnc is committed to improving our service to you

Naveen Pemmaraju

Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical trials that are investigating tagraxofusp. Currently, tagraxofusp is approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients older than two years old. There are a number of ongoing Phase II clinical trials in myelofibrosis and chronic myeloid leukemia (CML), including trials in combination with venetoclax or chemotherapy. There are also trials investigating triplet combinations with venetoclax and azacitidine in acute myeloid leukemia (AML). The use of tagraxofusp in post-transplant patients has not been studied yet, but there are clinical trials enrolling. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter